Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model

 
• By Tim Casey
  
Analysts think the model could allow more Medicaid coverage of cell and gene therapies for sickle cell disease. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Medicaid